Glutamate Receptors in Epileptogenesis

癫痫发生中的谷氨酸受体

• 批准号: 6780635
• 负责人: SUZANNE B BAUSCH
• 金额: $ 30.01万
• 依托单位: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-03-01 至 2008-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6780635
• 关键词: NMDA receptors; biological signal transduction; brain disorder chemotherapy; confocal scanning microscopy; electrophysiology; epilepsy; glutamate receptor; hippocampus; histology; immunocytochemistry; inhibitor /antagonist; laboratory rat; neural plasticity; nonhuman therapy evaluation; partial seizure; receptor expression; synapses; temporal lobe /cortex disorder; western blottings

DESCRIPTION (provided by applicant): Excessive N-methyl-D-aspartate receptor (NMDAR) activation is thought to contribute to pathophysiology in a variety of neurological disorders. This involvement led to the development of NMDAR antagonists for therapeutic applications. High-affinity competitive and noncompetitive NMDAR antagonists proved unsuitable for human use due to prominent adverse effects. High-affinity, competitive antagonists also can promote synaptic reorganization and glutamate receptor up-regulation in experimental systems, which may lead to anomalous neuronal circuits and individual synapse abnormalities. Moderate-affinity noncompetitive and NR2B-selective NMDAR antagonists elicit fewer adverse effects and remain viable therapeutic options. Whether these antagonists alter neuronal circuits and individual synapses remains largely unexplored. NMDAR antagonists hold promise to prevent acquired epilepsy. Current therapies target seizures associated with fully developed epilepsy, but cannot prevent epilepsy acquired following brain insult. Epileptogenesis, the process by which a normal brain becomes prone to chronic seizures, is associated with circuitry rearrangements and individual synapse abnormalities. Thus, NMDAR antagonists that induce synaptic reorganization and alter individual synapses may exacerbate rather than inhibit epileptogenesis. Our goal for the proposed study is to document the effects of three distinct classes of NMDAR antagonists (NR2B-selective, high-affinity competitive and moderate-affinity uncompetitive) on epileptogenesis and to determine whether the effects of different classes of NMDAR antagonists on epileptogenesis are associated with alterations in synaptic plasticity. These aims will be accomplished using a combination of pharmacological, electrophysiological, histological and histochemical approaches in a rat hippocampal slice culture model of epileptogenesis. Results from this study will provide new information about the benefits and potential drawbacks of chronic treatment with different classes of NMDAR antagonists. These data also will lead to a greater understanding of the role of synaptic plasticity in epileptogenesis. This information is crucial in providing a rational basis for development of therapies designed to prevent acquired epilepsy.

描述（由申请人提供）：过度的n -甲基- d -天冬氨酸受体（NMDAR）激活被认为有助于多种神经系统疾病的病理生理。这种参与导致了用于治疗应用的NMDAR拮抗剂的发展。高亲和力的竞争性和非竞争性NMDAR拮抗剂由于明显的副作用被证明不适合人类使用。在实验系统中，高亲和力的竞争性拮抗剂也可以促进突触重组和谷氨酸受体的上调，这可能导致神经元回路异常和个体突触异常。中等亲和力非竞争性和nr2b选择性NMDAR拮抗剂引起较少的不良反应，仍然是可行的治疗选择。这些拮抗剂是否会改变神经元回路和单个突触，在很大程度上仍未被研究。NMDAR拮抗剂有望预防获得性癫痫。目前的治疗针对与完全发展的癫痫相关的癫痫发作，但不能预防脑损伤后获得的癫痫。癫痫发生是正常大脑容易发生慢性癫痫的过程，它与电路重排和个别突触异常有关。因此，诱导突触重组和改变单个突触的NMDAR拮抗剂可能加剧而不是抑制癫痫发生。我们提出的研究目标是记录三种不同类型的NMDAR拮抗剂（nr2b选择性，高亲和力竞争和中等亲和力非竞争）对癫痫发生的影响，并确定不同类型的NMDAR拮抗剂对癫痫发生的影响是否与突触可塑性的改变有关。这些目标将在癫痫发生的大鼠海马切片培养模型中使用药理学，电生理，组织学和组织化学方法的组合来实现。这项研究的结果将提供关于使用不同类型的NMDAR拮抗剂进行慢性治疗的益处和潜在缺点的新信息。这些数据也将使我们对突触可塑性在癫痫发生中的作用有更深入的了解。这一信息对于为开发旨在预防获得性癫痫的治疗方法提供合理基础至关重要。